Table 1.
Effect of aprepitant on the antifungal activity of fluconazole (FLC), voriconazole (VRC), and itraconazole (ITC) against C. auris clinical isolates
|
C. auris Isolates |
MIC (µg/ml) |
Combination with FLC |
Combination with VRC |
Combination with ITC |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APR | FLC | VRC | ITC | APR/FLC (µg/ml) |
ƩFIC | Mode | APR/VRC (µg/ml) |
ƩFIC | Mode | APR/ITC (µg/ml) |
ƩFIC | Mode | |
| AR0381 | > 128 | 1 | 0.0078 | 0.25 | 0.5/0.5 | 0.50 | SYN | 8/0.007 | 1.06 | IND | 2/0.125 | 0.52 | ADD |
| AR0382 | 1 | 0.0625 | 0.25 | 1/0.5 | 0.51 | ADD | 8/0.031 | 0.56 | ADD | 8/0.0312 | 0.19 | SYN | |
| AR0383 | 256 | 0.5 | 0.5 | 2/256 | 1.02 | IND | 8/0.25 | 0.56 | ADD | 8/0.125 | 0.31 | SYN | |
| AR0384 | 128 | 0.5 | 0.25 | 2/64 | 0.52 | ADD | 8/0.25 | 0.56 | ADD | 8/0.0312 | 0.19 | SYN | |
| AR0385 | 256 | 4 | 0.5 | 2/256 | 1.02 | IND | 4/2 | 0.53 | ADD | 8/0.125 | 0.31 | SYN | |
| AR0386 | 256 | 2 | 0.5 | 16/128 | 0.63 | ADD | 4/1 | 0.53 | ADD | 8/0.125 | 0.31 | SYN | |
| AR0387 | 1 | 0.0312 | 0.125 | 0.5/0.5 | 0.50 | SYN | 4/0.015 | 0.53 | ADD | 8/0.0312 | 0.31 | SYN | |
| AR0388 | 256 | 0.5 | 1 | 8/8 | 0.09 | SYN | 8/0.062 | 0.19 | SYN | 2/0.125 | 0.14 | SYN | |
| AR0389 | 256 | 2 | 1 | 8/256 | 1.06 | IND | 8/2 | 1.06 | IND | 2/0.5 | 0.52 | ADD | |
| AR0390 | 256 | 0.5 | 1 | 8/8 | 0.09 | SYN | 8/0.062 | 0.19 | SYN | 4/0.125 | 0.16 | SYN | |
*ΣFICI (fractional inhibitory concentration index) was used to measure the interaction between the tested combinations. ΣFICI interpretation corresponded to the following definitions: synergism (SYN), ΣFICI ≤0.5; additivity (ADD), ΣFICI >0.5 and ≤1; and indifference (IND), ΣFICI >1 and ≤4.